2026年蔡磊致渐冻症病友的新年公开信：历史已被改写，渐冻症必然被攻克！

Core Viewpoint - The article emphasizes the significant advancements in the treatment of Amyotrophic Lateral Sclerosis (ALS) and the hope for future breakthroughs in medical science, particularly through collaboration among scientists, pharmaceutical companies, and patients [1][2][3]. Group 1: Treatment Advancements - The collaboration with Chinese scientists has led to the development of treatment drugs for SOD1 gene-type ALS, achieving world-leading clinical efficacy [1][2]. - Patients have reported dramatic improvements in their conditions, with some experiencing a 95% reduction in NFL (neurofilament light chain) levels, indicating significant recovery [1][8]. - The treatment has allowed patients to regain mobility and functionality, with some able to perform physical activities they could not do before [1][8]. Group 2: Research and Development - In 2025, the company facilitated nearly 100 ALS research projects in collaboration with over 60 top research teams and 50 biotech companies, resulting in breakthroughs in 15 drug pipelines and treatment technologies [11]. - The use of AI has accelerated research efforts, enabling the analysis of nearly 40,000 ALS research papers and hundreds of drug evaluations, significantly increasing research efficiency [11]. - The patient community has grown to over 18,000 registered individuals, providing a substantial database for real-world data research and clinical studies [11]. Group 3: Innovation in Care and Cost Reduction - A new care system for ALS patients has been established, focusing on comprehensive management to improve care quality and reduce costs [11][12]. - Collaborations with companies like Haier and JD Health have led to the development of customized, high-quality non-invasive ventilators at an 80% reduced cost for patients [11][12]. - The company has invested over 80 million yuan in research over the past 24 months, with a total investment exceeding 100 million yuan over six years, highlighting a commitment to advancing ALS treatment [11][12]. Group 4: Future Outlook - The year 2026 is anticipated to bring significant breakthroughs, with ongoing efforts to enhance AI-driven research and develop innovative care solutions [12]. - The company is exploring partnerships with robotics firms to create nursing robots that can assist with patient care, aiming to alleviate the burden on families [12]. - The overarching message is one of hope and determination, emphasizing that ALS can be conquered through collective efforts and scientific advancements [13].